A novel four-drug ablative regimen with hemopoietic stem cell rescue for patients with breast cancer: A phase II study

Roger D. Gingrich, Choon Kee Lee, Raymond Hohl, Jacqueline Joyce, Linda J. Burns, Kazumitsu Tamaki, B. Chen Wen, Shane Scott

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

High-dose chemotherapy and autologous hemopoietic stem cell transplantation (HSCT) may provide durable progression-free survival in some patients with stage IV breast cancer (S4Brca). We have studied a new four-drug intensive preparative regimen with HSCT in a group of 158 women with S4Brca to define the risk and potential benefit of this regimen in this patient population. From May 1988 through May 1997, 158 women with S4Brca at a single center were treated with cisplatin, etoposide, thiotepa, and cyclophosphamide (PETCy) plus autologous HSCT. Eligible patients were also treated with posttransplant involved-field radiation therapy. Patients with estrogen-receptor positive tumors not previously treated with tamoxifen also received this therapy for 5 years following transplantation. All patients experienced significant toxicity requiring blood-product support and parenteral nutrition. Eighteen patients (11%) died of regimen-related toxic events. With a median follow-up of 540 days for surviving patients, a retrospective Kaplan-Meier analysis projects an overall survival of 38 ± 8.5% (95% CI) at 890 days with a maximum follow-up of 8.8 years. For 52 patients in sensitive relapse, the median event-free survival time is 767 days, with 46.2 ± 15.3% (95% CI) predicted to be alive at 884 days with a maximal follow-up of almost 9 years. Nearly one-half of patients in this study with S4Brca in sensitive relapse have experienced durable remissions following PETCy ablation and HSCT. Although toxicity is significant, the PETCy regimen produces a favorable balance between efficacy (event-free survival) and treatment failure (relapse + regimen-related toxic death) compared with published results. These data suggest that within the high-dose range for preparative therapy, a steep dose-response may exist for breast cancer. Trials comparing the dose intensity of preparative regimens are warranted.

Original languageEnglish (US)
Pages (from-to)86-93
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume5
Issue number2
DOIs
StatePublished - Jan 1 1999

Fingerprint

Stem Cells
Breast Neoplasms
Stem Cell Transplantation
Pharmaceutical Preparations
Disease-Free Survival
Poisons
Recurrence
Thiotepa
Parenteral Nutrition
Kaplan-Meier Estimate
Etoposide
Tamoxifen
Treatment Failure
Estrogen Receptors
Cyclophosphamide
Cisplatin
Radiotherapy
Transplantation
Drug Therapy
Survival

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

Gingrich, Roger D. ; Lee, Choon Kee ; Hohl, Raymond ; Joyce, Jacqueline ; Burns, Linda J. ; Tamaki, Kazumitsu ; Wen, B. Chen ; Scott, Shane. / A novel four-drug ablative regimen with hemopoietic stem cell rescue for patients with breast cancer : A phase II study. In: Biology of Blood and Marrow Transplantation. 1999 ; Vol. 5, No. 2. pp. 86-93.
@article{8c283cd34b354902aff8f497566ab290,
title = "A novel four-drug ablative regimen with hemopoietic stem cell rescue for patients with breast cancer: A phase II study",
abstract = "High-dose chemotherapy and autologous hemopoietic stem cell transplantation (HSCT) may provide durable progression-free survival in some patients with stage IV breast cancer (S4Brca). We have studied a new four-drug intensive preparative regimen with HSCT in a group of 158 women with S4Brca to define the risk and potential benefit of this regimen in this patient population. From May 1988 through May 1997, 158 women with S4Brca at a single center were treated with cisplatin, etoposide, thiotepa, and cyclophosphamide (PETCy) plus autologous HSCT. Eligible patients were also treated with posttransplant involved-field radiation therapy. Patients with estrogen-receptor positive tumors not previously treated with tamoxifen also received this therapy for 5 years following transplantation. All patients experienced significant toxicity requiring blood-product support and parenteral nutrition. Eighteen patients (11{\%}) died of regimen-related toxic events. With a median follow-up of 540 days for surviving patients, a retrospective Kaplan-Meier analysis projects an overall survival of 38 ± 8.5{\%} (95{\%} CI) at 890 days with a maximum follow-up of 8.8 years. For 52 patients in sensitive relapse, the median event-free survival time is 767 days, with 46.2 ± 15.3{\%} (95{\%} CI) predicted to be alive at 884 days with a maximal follow-up of almost 9 years. Nearly one-half of patients in this study with S4Brca in sensitive relapse have experienced durable remissions following PETCy ablation and HSCT. Although toxicity is significant, the PETCy regimen produces a favorable balance between efficacy (event-free survival) and treatment failure (relapse + regimen-related toxic death) compared with published results. These data suggest that within the high-dose range for preparative therapy, a steep dose-response may exist for breast cancer. Trials comparing the dose intensity of preparative regimens are warranted.",
author = "Gingrich, {Roger D.} and Lee, {Choon Kee} and Raymond Hohl and Jacqueline Joyce and Burns, {Linda J.} and Kazumitsu Tamaki and Wen, {B. Chen} and Shane Scott",
year = "1999",
month = "1",
day = "1",
doi = "10.1053/bbmt.1999.v5.pm10371360",
language = "English (US)",
volume = "5",
pages = "86--93",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "2",

}

A novel four-drug ablative regimen with hemopoietic stem cell rescue for patients with breast cancer : A phase II study. / Gingrich, Roger D.; Lee, Choon Kee; Hohl, Raymond; Joyce, Jacqueline; Burns, Linda J.; Tamaki, Kazumitsu; Wen, B. Chen; Scott, Shane.

In: Biology of Blood and Marrow Transplantation, Vol. 5, No. 2, 01.01.1999, p. 86-93.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A novel four-drug ablative regimen with hemopoietic stem cell rescue for patients with breast cancer

T2 - A phase II study

AU - Gingrich, Roger D.

AU - Lee, Choon Kee

AU - Hohl, Raymond

AU - Joyce, Jacqueline

AU - Burns, Linda J.

AU - Tamaki, Kazumitsu

AU - Wen, B. Chen

AU - Scott, Shane

PY - 1999/1/1

Y1 - 1999/1/1

N2 - High-dose chemotherapy and autologous hemopoietic stem cell transplantation (HSCT) may provide durable progression-free survival in some patients with stage IV breast cancer (S4Brca). We have studied a new four-drug intensive preparative regimen with HSCT in a group of 158 women with S4Brca to define the risk and potential benefit of this regimen in this patient population. From May 1988 through May 1997, 158 women with S4Brca at a single center were treated with cisplatin, etoposide, thiotepa, and cyclophosphamide (PETCy) plus autologous HSCT. Eligible patients were also treated with posttransplant involved-field radiation therapy. Patients with estrogen-receptor positive tumors not previously treated with tamoxifen also received this therapy for 5 years following transplantation. All patients experienced significant toxicity requiring blood-product support and parenteral nutrition. Eighteen patients (11%) died of regimen-related toxic events. With a median follow-up of 540 days for surviving patients, a retrospective Kaplan-Meier analysis projects an overall survival of 38 ± 8.5% (95% CI) at 890 days with a maximum follow-up of 8.8 years. For 52 patients in sensitive relapse, the median event-free survival time is 767 days, with 46.2 ± 15.3% (95% CI) predicted to be alive at 884 days with a maximal follow-up of almost 9 years. Nearly one-half of patients in this study with S4Brca in sensitive relapse have experienced durable remissions following PETCy ablation and HSCT. Although toxicity is significant, the PETCy regimen produces a favorable balance between efficacy (event-free survival) and treatment failure (relapse + regimen-related toxic death) compared with published results. These data suggest that within the high-dose range for preparative therapy, a steep dose-response may exist for breast cancer. Trials comparing the dose intensity of preparative regimens are warranted.

AB - High-dose chemotherapy and autologous hemopoietic stem cell transplantation (HSCT) may provide durable progression-free survival in some patients with stage IV breast cancer (S4Brca). We have studied a new four-drug intensive preparative regimen with HSCT in a group of 158 women with S4Brca to define the risk and potential benefit of this regimen in this patient population. From May 1988 through May 1997, 158 women with S4Brca at a single center were treated with cisplatin, etoposide, thiotepa, and cyclophosphamide (PETCy) plus autologous HSCT. Eligible patients were also treated with posttransplant involved-field radiation therapy. Patients with estrogen-receptor positive tumors not previously treated with tamoxifen also received this therapy for 5 years following transplantation. All patients experienced significant toxicity requiring blood-product support and parenteral nutrition. Eighteen patients (11%) died of regimen-related toxic events. With a median follow-up of 540 days for surviving patients, a retrospective Kaplan-Meier analysis projects an overall survival of 38 ± 8.5% (95% CI) at 890 days with a maximum follow-up of 8.8 years. For 52 patients in sensitive relapse, the median event-free survival time is 767 days, with 46.2 ± 15.3% (95% CI) predicted to be alive at 884 days with a maximal follow-up of almost 9 years. Nearly one-half of patients in this study with S4Brca in sensitive relapse have experienced durable remissions following PETCy ablation and HSCT. Although toxicity is significant, the PETCy regimen produces a favorable balance between efficacy (event-free survival) and treatment failure (relapse + regimen-related toxic death) compared with published results. These data suggest that within the high-dose range for preparative therapy, a steep dose-response may exist for breast cancer. Trials comparing the dose intensity of preparative regimens are warranted.

UR - http://www.scopus.com/inward/record.url?scp=0032604707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032604707&partnerID=8YFLogxK

U2 - 10.1053/bbmt.1999.v5.pm10371360

DO - 10.1053/bbmt.1999.v5.pm10371360

M3 - Article

C2 - 10371360

AN - SCOPUS:0032604707

VL - 5

SP - 86

EP - 93

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 2

ER -